Khan Bilal Arshad 4
4 · SpyGlass Pharma, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
SpyGlass Pharma (SGP) Director Khan Bilal Arshad Buys 135,000 Shares
What Happened
Khan Bilal Arshad, a director of SpyGlass Pharma, reported two purchases on Feb 9, 2026: 20,000 shares and 115,000 shares, each at $16.00 per share, for a combined acquisition of 135,000 shares valued at approximately $2,160,000. Both transactions are coded "P" (purchase/open market or private purchase), which is a direct buy of stock rather than an option exercise or award.
Key Details
- Transaction dates/prices: Feb 9, 2026 — 20,000 shares @ $16.00; Feb 9, 2026 — 115,000 shares @ $16.00.
- Total acquired: 135,000 shares for ~$2,160,000.
- Shares owned after transaction: Not specified in the supplied Form 4 data.
- Footnote F1: Some shares are held by New World Medical, Inc.; Mr. Arshad is CEO of New World Medical and has voting/investment control over shares held by that entity but disclaims beneficial ownership except for any pecuniary interest.
- Filing: Form 4 filed Feb 11, 2026 reporting Feb 9 transactions — appears timely (filed within the SEC’s two-business-day window).
Context
These were outright purchases (code P), not option exercises, awards, or gifts. Purchases by insiders are often watched by investors as a potential positive signal, but they do not guarantee future company performance. The footnote clarifies that some holdings are through New World Medical, indicating institutional/affiliate holdings distinct from Mr. Arshad’s personal beneficial ownership.
Insider Transaction Report
- Purchase
Common Stock
2026-02-09$16.00/sh+20,000$320,000→ 25,450 total - Purchase
Common Stock
[F1]2026-02-09$16.00/sh+115,000$1,840,000→ 251,427 total(indirect: See footnote)
Footnotes (1)
- [F1]Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares.